Journal of Thoracic Oncology (JTO), July 2021, Volume 16, Issue 7
Journal | English | 2021
Image For Activity Cover
Credit Offered
No Credit Offered
In This Issue
  • Dr. Gouri Shankar Bhattacharyya, MD, PhD, FRCP: In Memoriam (October 31, 1958–May 1, 2021)
  • From the IASLC Tobacco Control Committee
  • Do Cancer Screening Researchers Have a Continuing Ethical Obligation to Their Study Subjects?
  • Pursuing Immunotherapeutic Targets in SCLC
Editorial - Lung Cancer Worldwide
  • Lung Cancer in Greece
Statistics in Thoracic Oncology
  • Time-To-Event Data: An Overview and Analysis Considerations
State of the Art - Concise Reviews
  • Stereotactic Radiation for Lung Cancer: A Practical Approach to Challenging Scenarios
  • Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors
  • Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta-Analysis
Original Articles
  • Clinical Significance of Lung-RADS Category 3 Lesions in the National Lung Screening Trial
  • Cannabis Use, Pulmonary Function, and Lung Cancer Susceptibility: A Mendelian Randomization Study
  • Timing and Origins of Local and Distant Metastases in Lung Cancer
  • Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers
  • Genomic and Clinical Significance of Multiple Primary Lung Cancers as Determined by Next-Generation Sequencing
  • SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition
  • Invasive Mucinous Adenocarcinomas With Spatially Separate Lung Lesions: Analysis of Clonal Relationship by Comparative Molecular Profiling
  • The HILUS-Trial—a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy
  • Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC
Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO emphasizes a multidisciplinary approach and includes original research reviews and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology. The journal is interested in receiving manuscripts dealing with epidemiology, prevention, screening, early detection, staging, cure, and treatment of thoracic malignancies. Submissions on tobacco control and cessation are of interest, particularly where there is direct relevance to lung cancer epidemiology and therapeutic outcomes. The Journal also welcomes submissions on pathologic and histologic classification and novel imaging and bronchoscopic approaches. Submissions regarding novel systemic therapies, particularly in the fields of biomarker targets, genomics, immunology, and cellular therapies are of interest. Novel radiotherapy and surgical techniques are of interest. Submission of randomized phase II and phase III trials, as well as meta analyses of individual participant data, are encouraged. Basic science studies must have direct clinical and translational relevance.

Authors are also welcome to submit to the journal's open access companion title, JTO Clinical and Research Reports, which welcomes a range of manuscripts from subset analyses of published trials to high-quality case reports
Powered By